12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Company News  |  Deals

Allos, Spectrum Pharmaceuticals deal

Spectrum completed its acquisition of cancer company Allos for $1.82 per share...

Read the full 40 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >